Table 5.
Significant associations between SNPs and measures of brain atrophy.
| Medial temporal lobe atrophy MTA |
Posterior atrophy PA |
Global cerebral atrophy-frontal GCA-F |
Fazekas_scale |
|
|---|---|---|---|---|
| β (p-value) | β (p-value) | β (p-value) | OR [C.I. 95%]; p-value | |
| rs17213159-FOXP2 | 0.534 (0.083) | 0.577 (0.077) | 0.490 (0.079) | 1.56 [0.22–10.95]; 0.653 |
| rs10230373-CNTNAP2 | −0.821 (0.090) | 0.117 (0.811) | −0.168 (0.727) | – |
| rs826644-CNTNAP2 | −0.088 (0.838) | 0.271 (0.498) | −0.053 (0.895) | 11.86 [0.68–20.4]; 0.088 |
| rs13045348-PRNP | −0.268 (0.567) | 0.985 (0.022) | 0.443 (0.295) | 0.82 [0.09–7.05]; 0.861 |
| rs2972106-PRNP | 0.003 (0.994) | −0.256 (0.556) | −0.034 (0.935) | 13.88 [1.15–16.74]; 0.038 |
MTA: Medial temporal lobe atrophy; PA: Posterior atrophy; GCA-F: Global cerebral atrophy-frontal sub-scale; β (p-value) refers to linear regression analysis; OR (C.I. 95%) p-value refers to logistic regression analysis. In both cases the most significant genetic model was the dominant.